Petros Pharmaceuticals, Inc. (PTPI)
PTPI moved a median of -2.52% 30 minutes after news, and -3.71% by the close. How PTPI actually reacts to news — the realized, point-in-time move the market made, measured across 118 labeled events over the last three years with zero look-ahead.
PTPI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.04% | 36% | 113 |
| 30-min | -2.52% | 24% | 115 |
| 60-min | -2.85% | 26% | 116 |
| to close | -3.71% | 27% | 118 |
| Middle 50% of PTPI reactions | -6.38% to 0.00% |
|---|---|
| Median reaction (30-min) | -2.52% |
| Measured reactions | 118 |
Half of all Petros Pharmaceuticals, Inc. news events land between -6.38% and +0.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PTPI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PTPI's baseline. Nothing else.
Recent PTPI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Petros Pharmaceuticals, For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -17.50% | |
| Form 10-Q Petros Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -10.00% | |
| Form 8-K Petros Pharmaceuticals, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -21.62% | -20.27% | |
| Form 8-K Petros Pharmaceuticals, For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | -20.29% | -10.87% | |
| Form 10-Q Petros Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -11.11% | -5.56% | |
| Form 10-K Petros Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +13.33% | |
| Form NT 10-K Petros Pharmaceuticals, For: Dec 31 | SEC filing · Form NT | SEC EDGAR | -1.72% | -6.32% | |
| Form 8-K Petros Pharmaceuticals, For: Jan 01 | SEC filing · Form 8-K | SEC EDGAR | -12.94% | -6.62% | |
| Form 8-K Petros Pharmaceuticals, For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | -0.51% | +4.54% | |
| Form 8-K Petros Pharmaceuticals, For: Aug 29 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.91% | |
| Form 10-Q Petros Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.29% | |
| Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position | Press release | ACCESS Newswire | +0.00% | -1.17% | |
| Form 8-K Petros Pharmaceuticals, For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +3.99% | +9.13% | |
| Form 8-K Petros Pharmaceuticals, For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +6.04% | +2.79% | |
| Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets | Press release | ACCESS Newswire | +6.04% | +2.79% | |
| Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer | Press release | ACCESS Newswire | -5.91% | -6.13% | |
| Form 10-Q Petros Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -9.87% | -11.27% | |
| Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform | Press release | ACCESS Newswire | -3.03% | -8.16% | |
| Form 8-K Petros Pharmaceuticals, For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | -2.78% | -11.23% | |
| Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches | Press release | ACCESS Newswire | -9.41% | -15.63% | |
| Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms | Press release | ACCESS Newswire | -11.75% | -67.50% | |
| Form 8-K Petros Pharmaceuticals, For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | +4.74% | +14.71% | |
| Form 8-K Petros Pharmaceuticals, For: Apr 05 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | -4.80% | |
| Form 10-K Petros Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.58% | +35.48% | |
| Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications | Press release | ACCESS Newswire | -3.82% | +0.00% | |
| Form DEF 14A Petros Pharmaceuticals, For: Apr 10 | SEC filing · Form DEF | SEC EDGAR | +8.33% | +15.06% | |
| Form PRER14A Petros Pharmaceuticals, | SEC filing · Form PRER14A | SEC EDGAR | +0.12% | -5.00% | |
| Form PRE 14A Petros Pharmaceuticals, For: Mar 07 | SEC filing · Form PRE | SEC EDGAR | +0.39% | -8.54% | |
| Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study | Press release | ACCESS Newswire | -10.81% | -14.66% | |
| Form 8-K Petros Pharmaceuticals, For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | +1.56% | -3.69% | |
| Form EFFECT Petros Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | -14.44% | -14.81% | |
| Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants | Press release | ACCESS Newswire | -14.44% | -14.81% | |
| Form S-1/A Petros Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | +54.09% | -6.39% | |
| Form S-1MEF Petros Pharmaceuticals, | SEC filing · Form S-1MEF | SEC EDGAR | -14.44% | -14.81% | |
| Form S-1/A Petros Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | -2.05% | -2.44% | |
| Form S-1/A Petros Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | -3.05% | -6.92% | |
| Form 8-K Petros Pharmaceuticals, For: Jan 23 | SEC filing · Form 8-K | SEC EDGAR | +2.37% | -5.39% | |
| Form S-1 Petros Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | +2.37% | -5.39% | |
| Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules | Press release | Accesswire | +2.55% | -11.04% | |
| Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment” | Press release | Accesswire | -7.07% | -17.39% | |
| Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually | Press release | Accesswire | -6.48% | +61.24% | |
| Form 8-K Petros Pharmaceuticals, For: Dec 10 | SEC filing · Form 8-K | SEC EDGAR | -6.48% | +61.24% | |
| Form 8-K Petros Pharmaceuticals, For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | -2.72% | +5.02% | |
| Form DEFA14A Petros Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | -0.04% | -3.46% | |
| Form 10-Q Petros Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.21% | -3.46% | |
| Form ARS Petros Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.65% | -0.33% | |
| Form DEF 14A Petros Pharmaceuticals, For: Nov 20 | SEC filing · Form DEF | SEC EDGAR | +0.65% | -0.33% | |
| Form 8-K Petros Pharmaceuticals, For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | +0.77% | +28.43% | |
| Form 8-K Petros Pharmaceuticals, For: Oct 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.72% | |
| Form PRE 14A Petros Pharmaceuticals, For: Nov 20 | SEC filing · Form PRE | SEC EDGAR | -1.96% | +14.31% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PTPI section they belong to.
Where else PTPI is measured.
PTPI earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Petros Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled PTPI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 118 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 24% of PTPI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PTPI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.